Login to Your Account



Manufacturing Capability 'The Prize'

Avant, Celldex Plan Merger; New Company Worth $115M

By Randall Osborne


Tuesday, October 23, 2007
The investor thrill that cutbacks last spring failed to provide for Avant Immunotherapeutics Inc. came in spades with news of the company's merger with Celldex Therapeutics Inc., and the all-stock deal creates a new firm worth about $115 million, (based on Avant's closing price Oct. 19), giving privately held Celldex about 58 percent ownership of the new company. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription